The Perpetual Money Machine

Plus, What to Make of Apple 2.0   Jan 31, 2019   Good News From the Fed and Apple Sets the Market Loose As an old ad slogan goes, "Life comes at you fast." Two pieces of market news yesterday show just how quickly things can change. In December, the Federal Reserve raised the Federal Funds target rate a quarter point, from 2.25% to 2.50%. That was widely expected, and the market didn't really respond, but things changed mere minutes later during Fed Chairman Jerome Powell's press conference. If you watched the December press conference live and the market at the same time, as I did, you saw the market turn downward as Powell affirmed that we should expect two more rate increases in 2019 and that the Fed would continue with its balance sheet reduction program -- allowing $50 billion a month to run off. The market r

You are receiving this message because you opted in to receive information about our upcoming campaigns from InvestorPlace. If you don’t want to receive messages about this campaign in the future you can unsubscribe  here  but you will no longer receive reminders and supporting content for this campaign.   Dear Reader, FDA approval for a breakthrough drug is one of the biggest wealth-creation events in the stock market. I’ve been tracking a tiny, $7 million firm that’s currently in Phase 3 trials and could be on the verge of receiving final government approval. This new treatment could result in a new leader in one of the biggest drug markets of all time while minting a new batch of millionaires for those who invested early. But today is your final chance to receive my full analysis on this special situation, including more than $14,000 worth of bonuses that come with it. This includes an entire FREE bonus year to

You are receiving this message because you opted in to receive information about our upcoming campaigns from InvestorPlace. If you don’t want to receive messages about this campaign in the future you can unsubscribe  here  but you will no longer receive reminders and supporting content for this campaign.   Dear Reader, I hope you made it to Matt McCall’s online event, the Blockbuster FDA Approval Summit 2019. If you weren’t able to view Matt’s presentation yet, you can watch a recap right now by clicking here . Insiders are saying this Phase 3 treatment is “the biggest improvement in cancer surgery in 50 years” and “an enormous scientific breakthrough.” One tiny, $7 million firm has filed a patent on it and could soar as we move closer to final FDA review. Although this small company is still private, Matt and his team of analysts have figured out a little-known way to purchase shares in its “silent partner” on the

Readers attack and defend our Monday Digest   Jan 30, 2019   Gold gains keep coming ... The autonomous vehicle trend sees another milestone ... And readers weigh in on legalized marijuana Monday's Digest featured the emails of three readers who had taken issue with our coverage of the legal marijuana trend. The volume of emails we received in response to that issue dwarfed anything we've seen in the history of the InvestorPlace Digest . A sincere "thank you" to everyone who wrote in to share their opinions. We value your perspectives and genuinely appreciate your time in writing us. We're happy to share some of that feedback at the end of this issue -- as you'll see, our readers hold strongly divergent opinions. But first, since our priority is helping readers grow their wealth, let's turn to recent market news. ***Yesterday, gold hit an eight-mo

Must-read market alert from legendary investor tells you exactly what to do now Dear Investor, There is only one type of stock you should own in today’s volatile market.  An unprecedented flood of money will be rushing into these unique stocks in the weeks ahead. I’m talking about $4.8 billion dollars a DAY. And that mountain of cash will make these stocks practically bulletproof, protecting them from market volatility. It will also propel them higher the further we get into 2019. I call them “money magnets,” and they are the #1 place to put you

You are receiving this message because you opted in to receive information about our upcoming campaigns from InvestorPlace. If you don’t want to receive messages about this campaign in the future you can unsubscribe  here  but you will no longer receive reminders and supporting content for this campaign.   Dear Reader, There’s only 24 hours left until the Blockbuster FDA Approval offer expires . I’ve uncovered a little-known biotech company with just $7 million in revenue that could soon take on a $100 billion drug market. But the clock is ticking… This is your final chance to learn how to get in during the early stages… before final FDA review has occurred, and the biggest gains typically follow. Until midnight tomorrow, you can still become a member of my elite high-growth technology research advisory… and receive an entire FREE bonus year. We’re also including $14,696 worth of high-growth investment research bo

Plus, PayPal stock hits a 52-week high   Jan 29, 2019   Nvidia Sinks on Guidance Downgrade Nvidia was the market-driving news yesterday as it made a huge change to its guidance for the quarter. For those not familiar with Nvidia, its graphic cards are used in video games, professional visualization, data center and automotive applications to improve the processing capabilities of computers. Their technology is going to be used in many of the future trends we discuss in the Digest , such as autonomous vehicles and electric cars. Yesterday, Nvidia announced that it is now expecting revenue for the quarter to be $2.20 billion, plus or minus 2% -- a major drop from the previous revenue guidance of $2.70 billion, plus or minus 2%. Analysts also were expecting the manufacturer of graphics cards to report revenue of $2.70 billion for the quarter. Nvidia laid a lot of the

This one recommendation could deliver 1,000% or more Dear Investor, Forget about the shaky markets we’ve had over the last few weeks … If you’re like me, you’ll see this as an amazing buying opportunity for a small group of Breakthrough Stocks . When these stocks beat expectations… it can send share prices soaring 50% or more in just a few short weeks. Setting up my readers for explosive gains in just a short amount of time. In fact, my readers saw gains like… 61% in a little more than a month on a computer company … 47% in 43 days on a software developer… 51% in less than two months on a medtech small cap… 50% in 6 weeks on a consumer products company… And even 81% in 42 days on a tech company! That’s over 290% in cumulative gains in less than two months. Which is why I decided to open up a few spots in my Breakthrough Stocks

You are receiving this message because you opted in to receive information about our upcoming campaigns from InvestorPlace. If you don’t want to receive messages about this campaign in the future you can unsubscribe  here  but you will no longer receive reminders and supporting content for this campaign.   Dear Reader, This is your final opportunity to sign up for my elite high-growth technology research advisory and receive a FREE bonus year. It’s called Early Stage Investor and it utilizes the same system from my days of managing money for America’s wealthiest individuals. I use this system to find small, barely known companies with future technology breakthroughs that could lead to triple- or even quadruple-digit gains. In the past, I’ve helped nonprofessionals see gains you’d typically only see inside an investment bank, like 528% with Neogen, 561% with Insulet, and 2,438% with Stamps.com. But Thursday is the final